

## ASX Announcement | 22 November 2023: AdAlta Limited (ASX:1AD)

### Results of Annual General meeting

AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body® platform advises that its Annual General Meeting was held today at 11:00am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary. All resolutions were carried with support of more than 98% of shares voted.

This ASX announcement has been authorised for release by Tim Oldham CEO & Managing Director of AdAlta Limited (ASX:1AD).

#### For further information, please contact:

**AdAlta Limited (ASX:1AD)**  
Tim Oldham  
CEO & Managing Director  
P: +61 3 9479 5159  
E: t.oldham@adalta.com.au

**Media & Investor Enquiries**  
The Capital Network  
Julia Maguire  
P: +61 2 8999 3699  
E: julia@thecapitalnetwork.com.au

#### About AdAlta Limited

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body® technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body® technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body® platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

**For more information**

To learn more, please visit: [www.adalta.com.au](http://www.adalta.com.au)

# Disclosure of Proxy Votes

## AdAlta Limited

Annual General Meeting

Wednesday, 22 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	224,913,345	220,483,040 98.03%	2,809,652 1.25%	1,046,375	1,620,653 0.72%	256,821,332 98.92%	2,809,652 1.08%	1,046,375	-
2 Re-election of Director – Dr David Fuller	P	227,412,847	225,748,495 99.27%	43,699 0.02%	0	1,620,653 0.71%	262,854,693 99.98%	43,699 0.02%	0	Passed
3 Ratification of prior issue of Shares to nominee of Grannus Securities	P	226,001,905	222,823,636 98.59%	1,588,613 0.70%	1,410,943	1,589,656 0.70%	259,898,837 99.39%	1,588,613 0.61%	1,410,943	Passed
4 Ratification or prior issue of Shares to nominee of Spark+	P	226,001,906	222,823,636 98.59%	1,588,617 0.70%	1,410,943	1,589,653 0.70%	259,898,834 99.39%	1,588,617 0.61%	1,410,943	Passed
5 Ratification of prior issue of Options to Peak Asset Management	P	223,279,011	218,766,868 97.98%	2,922,490 1.31%	77,072	1,589,653 0.71%	253,942,066 98.14%	4,822,490 1.86%	77,072	Passed
6 Approval of issue of Options to Dr Timothy Oldham, Director of the Company	P	225,095,350	221,497,198 98.40%	1,978,499 0.88%	864,375	1,619,653 0.72%	257,834,490 99.24%	1,978,499 0.76%	864,375	Passed
7 Approval of issue of Options to Dr Paul MacLeman, Director of the Company	P	225,095,351	221,522,198 98.41%	1,953,500 0.87%	864,375	1,619,653 0.72%	255,959,490 98.52%	3,853,500 1.48%	864,375	Passed
8 Approval of issue of Options to Dr Robert Peach, Director of the Company	P	225,095,352	221,497,198 98.40%	1,978,501 0.88%	2,317,501	1,619,653 0.72%	255,934,490 98.51%	3,878,501 1.49%	2,317,501	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of issue of Options to Dr David Fuller, Director of the Company	P	225,095,353	221,497,198 98.40%	1,978,502 0.88%	864,375	1,619,653 0.72%	255,934,490 98.51%	3,878,502 1.49%	864,375	Passed
10 Approval of 10% placement capacity	P	212,472,173	208,866,262 98.30%	2,016,258 0.95%	30,010	1,589,653 0.75%	245,941,460 99.19%	2,016,258 0.81%	30,010	Passed

